What is United Therapeutics's tyvaso DPI — gross profit?

United Therapeutics (UTHR) reported tyvaso DPI — gross profit of $247.1M in Q1 2026.

How has United Therapeutics's tyvaso DPI — gross profit changed year-over-year?

United Therapeutics's tyvaso DPI — gross profit decreased by 2.9% year-over-year, from $254.4M to $247.1M.

What does tyvaso DPI — gross profit mean?

Calculated as the total revenue from a specific product line minus the direct costs of sales associated with that product. This metric measures the profitability of a product before accounting for research and development, marketing, or administrative expenses. It provides insight into the underlying margin profile and pricing power of the therapeutic asset.

United Therapeutics UTHR Tyvaso DPI — Gross Profit

Other product segments

Orenitram

$128.2M+14.1%

Nebulized Tyvaso

$118.6M-23.6%

Remodulin

$110.5M-11.2%

Unituxin

$48.6M-8.3%

Adcirca

$1.9M-44.1%

Similar metrics at other companies

MNKDTyvaso DPI — Percentage Of Royalty On Net Sales

10%0.0pp

MNKDTyvaso DPI — Percentage Of Royalty On Net Revenue

10%0.0pp

MNKDCollaborations And Services Related To Tyvaso DPI — Cost Of Revenue

$10M-27.0%

OPKDiagnostics — Gross Profit

$16.04M-12.5%

OGNVytorin — Revenue

$21M-8.7%

MLABBiopharmaceutical Development — Gross Profit

$5.2M-28.3%

Other financials

Income statement

See full

Revenue$781.5M-1.6%

Gross profit$648.1M-7.7%

Operating income$325.8M-14.9%

Net income$274.9M-14.7%

EPS (diluted)$5.82-12.2%

Balance sheet

See full

Cash & equivalents$1.3B-32.6%

Total debt$12.2M—

Total equity$5.9B-13.3%

Total assets$6.7B-13.3%

Cash flow

See full

Operating cash flow$463.3M+0.5%

CapEx$100.8M+34.6%

Free cash flow$362.5M-6.2%

Valuation

See full

Market cap$23B+84.1%

P/E17.9×+7.8×

P/S7.3×+3.2×

Profitability

See full

Gross margin86.6%-2.4pp

Operating margin45.3%-1.6pp

Net margin40.6%+0.2pp

FCF margin32.1%-5.6pp

Returns & leverage

See full

Return on equity20.3%+0.3pp

Debt / equity0×—

Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GrossProfit.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's tyvaso dpi — gross profit.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is United Therapeutics's tyvaso DPI — gross profit?: United Therapeutics (UTHR) reported tyvaso DPI — gross profit of $247.1M in Q1 2026.
How has United Therapeutics's tyvaso DPI — gross profit changed year-over-year?: United Therapeutics's tyvaso DPI — gross profit decreased by 2.9% year-over-year, from $254.4M to $247.1M.
What does tyvaso DPI — gross profit mean?: Calculated as the total revenue from a specific product line minus the direct costs of sales associated with that product. This metric measures the profitability of a product before accounting for research and development, marketing, or administrative expenses. It provides insight into the underlying margin profile and pricing power of the therapeutic asset.